MannKind Q3 revenue rises on royalty gains

Overview

• Biopharma firm's Q3 2026 revenue rose 24% yr/yr, driven by Furoscix and royalty gains

• Commercial product revenue more than doubled, led by Furoscix and Afrezza growth

• Company posted a net loss as launch costs and SG&A expenses increased

Outlook

• Company expects Furoscix revenue in Q4 to exceed first-half 2026 levels

• Company sees expanded opportunity from Furoscix ReadyFlow launch

• Company advancing MNKD-201 into global Phase 2 trial

Result Drivers

• FUROSCIX LAUNCH - Rapid adoption of Furoscix ReadyFlow and increased utilization drove commercial revenue growth

• AFREZZA PEDIATRIC LAUNCH - Uptake in pediatric prescriptions contributed to Afrezza sales growth

• ROYALTY INCREASE - Higher Tyvaso DPI sales at United Therapeutics boosted royalty revenue

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for MannKind Corporation is $8.00, about 103.6% above its November 4 closing price of $3.93

Reuters Recommended Reads

• Nov 4 - United Therapeutics Q3 revenue rises 4%, beats estimates

• Nov 3 - Pfizer Q3 revenue beats estimates on new launches; raises guidance

• Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)